News

Vail Successfully Completes Initial Fundraise

Vail Successfully Completed (Oversubscribed) Initial Funding At the end of August 2021, Vail Scientific successfully closed an oversubscribed round. The round was led by Vail Investor Group and its leader and Vail board member, Mike Nathan. Nathan shares, “I, along with the Vail Investor Group, have a real passion for transformative innovation. Sepsis diagnosis is […]

Vail Successfully Completes Initial Fundraise Read Post »

Vail Launches NO-SEPSIS Trial

Our work continues because patients with sepsis cannot wait. Vail Scientific is pleased to announce the official start of its proof-of-concept NO-SEPSIS clinical study with HealthPartners. It will be conducted at HealthPartners facilities in the Minneapolis-St. Paul area. Thanks to our previous pilot study we were able to identify two statistically significant measurements. These measurements

Vail Launches NO-SEPSIS Trial Read Post »